Neumora reports favorable NMRA-215 toxicology data, still targets Q4 2026 IND

Neumora Therapeutics said on July 27, 2026 that it obtained favorable results from a repeat pre-clinical toxicology study of NMRA-215, an oral NLRP3 inhibitor being developed for obesity and cardiometabolic disease. The company said it plans to submit an IND in the fourth quarter of 2026 and to initiate a Phase 1 study by the end of 2026.¹

The repeat study followed an earlier one in which problems emerged. Neumora had conducted a 13-week toxicology study in rats after a prior study showed unexpected in-life adverse findings in 5 of 142 animals.¹ The company opened a for-cause audit of that earlier study, which turned up various discrepancies and a number of critical audit observations.¹

In the follow-up work, a repeat 13-week rat toxicology study in 162 animals showed no instances of unexpected in-life adverse findings.¹ Based on the audit observations, the repeat study data, and results from earlier 28-day rat, 28-day dog and 13-week dog toxicology studies, Neumora said it continues to believe the prior adverse findings were not related to NMRA-215, and it plans to submit the IND application in the fourth quarter of 2026.¹

Chief scientific officer Nick Brandon said the compound's properties allow it to achieve sustained IC90 coverage in the brain, which produced compelling pre-clinical efficacy in a diet-induced obesity mouse model, including class-leading weight loss as a monotherapy and additive weight loss when combined with semaglutide.¹ The filing notes that actual results could differ from these forward-looking statements due to risks including the company's receipt and review of the histopathology report for the three-month toxicity study, among other factors.¹